In this partnership, the three stakeholders will establish a phased malaria eradication project for most endemic districts of Madhya Pradesh.
Moreover, the company and the Indian Council of Medical Research (ICMR) may enter a joint drug development programme to manufacture new patented drugs. ICMR comes under the Union ministry of health and family welfare.
Also Read
| KEY TAKEAWAYS |
|
"We are very open to such drug development. It would not be restricted to malaria-specific drugs. Most companies in India are not developing any new drugs. Sun Pharma can use our strengths (like clinical data) and we can use their manufacturing capability to develop new drugs," said Soumya Swaminathan, director general, ICMR.
The first district in Madhya Pradesh to be targeted through this PPP would be Mandla, where 57 per cent of the population belong to Scheduled Tribes. The aim is to eradicate malaria in three to five years. Mandla district has a population of around one million and has over 12,000 villages.
"The idea to start from one district is to understand what the problems are. Gaining knowledge from the experience, we would use it to roll out a larger programme once this project is successful," said Dilip Sanghvi, managing director, Sun Pharmaceuticals.
One part of this PPP would be the malaria elimination in Mandla, while the other would be to prevent its re-introduction in the district later. For that, the company would publicly share data that it gathers from the district.
The stakeholders will jointly undertake the eradication programme by setting up management and technical oversight for disease surveillance and elimination.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)